
An Australian medical technology company is making waves in the fight against endometriosis, a chronic and often debilitating condition that affects one in ten women globally. Proteomics International, in collaboration with researchers at the University of Melbourne and the Royal Women’s Hospital, is on the verge of launching the world’s first blood test to diagnose endometriosis. Dubbed PromarkerEndo, this test could transform the diagnostic process for a disease that has long been underserved by medical advancements. “This advancement marks a significant step toward non-invasive, personalized care for a condition that has long been underserved by current medical approaches,” said Richard Lipscombe, managing director of Proteomics International, in a recent press release. In recent peer-reviewed trials, the test demonstrated a remarkable 99.7 percent accuracy in distinguishing severe endometriosis cases from those without the disease. Even in the early stages, where markers are harder to detect, the test maintained an accuracy rate exceeding 85 percent.
More: